Impact of recipient age and preoperative fasting blood glucose level as the risk factors of living donor liver transplantation in cirrhotic patients in the recent comprehensive era with knowledge of indications: Recent status in a Japanese single center

Hepatology Research

Volumn 43, Issue 11, 2013, Pages 1148-1155

  Ishigami, Masatoshi ^a   Onishi, Yasuharu ^a   Kamei, Hideya ^a   Kiuchi, Tetsuya ^a   Katano, Yoshiaki ^a   Itoh, Akihiro ^a   Hirooka, Yoshiki ^a   Goto, Hidemi ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Fasting blood glucose; Liver cirrhosis; Living donor liver transplantation; Recipient age; Risk factors

Indexed keywords

CALCINEURIN INHIBITOR; CHOLESTEROL; CREATININE; GLUCOSE; HEMOGLOBIN A1C; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; BLOOD COMPATIBILITY; CHOLESTEROL BLOOD LEVEL; CIRRHOTIC PATIENT; CREATININE BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GRAFT RECIPIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; PATIENT; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84886839786     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12067     Document Type: Article

References (37)

1. Tsao GG, Lim J, Members of Veterans Affairs Hepatitis C Resource Center Program. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 2009; 104: 1802-1829.
2. Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology 1998; 27: 264-272.
3. Imperiae TF, Chalasani N. A meta-analysis of endoscopic variceral ligation for primary prophylaxis of esophageal variceral bleeding. Hepatology 2001; 33: 802-807.
4. Planas R, Ballaeste B, Alvarez MA etal. Natural history of decompensated hepatitis C virus related cirrhosis. J Hepatol 2004; 40: 823-830.
5. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993; 18: 353-358.
6. Chalasani N, Said A, Ness R, Hoen H, Lumeng L. Screening for hepatocellular carcinoma in patients with advanced cirrhosis. Am J Gastroenterol 1999; 94: 2988-2993.
7. Liver transplantation in Japan-registry by the Japanese Liver Transplant Society. 2009. Available at: http://jlts.umin.ac.jp/annual/registry(2009).pdf. Accessed July 25, 2010.
8. Data from Japan Organ Transplantation Network. 2010. Available at: http://www.jotnw.or.jp/datafile/offer/index.html. Accessed July 25, 2010.
9. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010; 10: 1003-1019.
10. Roels L, Rahmel A. The European experience. Transplant Int 2011; 24: 350-367.
11. Moon DB, Lee SG. Liver transplantation. Gut Liver 2009; 3: 145-165.
12. Surman OS. The ethics of partial-liver donation. N Engl J Med 2002; 346: 1038.
13. Umeshita K, Fujiwara K, Kiyosawa K etal. Japansese Liver Transplantation Society. Operative morbidity of living donors in Japan. Lancet 2003; 362: 687-690.
14. Mazzaferro V, Regalia E, Doci R etal. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
15. Markowitz JS, Martin P, Conrad AJ etal. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-589.
16. Marzano A, Salizzoni M, Debernardi-Venon W etal. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34: 903-910.
17. Kiuchi T, Kasahara M, Uryuhara K etal. Impact of graft size mismatching on graft prognosis in liver transplantation from live donors. Transplantation 1999; 67: 321-327.
18. Shimazu M, Kitajima M. Living donor liver transplantation with special reference to ABO-incompatible grafts and small-for-size grafts. World J Surg 2004; 28: 2-7.
19. Yoshizawa A, Sakamoto S, Ogawa K etal. New protocol of immunosuppression for liver transplantation across ABO barrier: the use of Rituximab, hepatic arterial infusion, and preservation of spleen. Transplant Proc 2005; 37: 1718-1719.
20. Raut V, Uemoto S. Management of ABO-incompatible living donor liver Transplantation: past and present trends. Surg Today 2011; 41: 317-322.
21. Tanabe M, Kawachi S, Obara H etal. Current progress in ABO-incomaptible liver transplantation. Eur J Clin Invest 2010; 40: 943-949.
22. Yao FY, Ferrell L, Bass NM etal. Liver Tranpsplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403.
23. Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo university series. Dig Dis 2007; 25: 310-312.
24. Ito T, Takada Y, Ueda M etal. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl 2007; 13: 1637-1644.
25. Lee SG, Hwang S, Moon DB etal. Expanded indication of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 2008; 14: 935-945.
26. Selzner N, Renner EL, Selzner M etal. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation 2009; 88: 1214-1221.
27. Gallegos-Orozco JF, Yosephy A, Noble B etal. Natural history of post-liver transplantation hepatitis C: a review of factors that may influence its course. Liver Transpl 2009; 15: 1872-1881.
28. Levy MF, Somasunder PS, Jennings LW etal. The elderly liver transplant recipient: a call for caution. Ann Surg 2001; 233: 107-113.
29. Garcia CE, Garcia RFL, Mayer AD, Neuberger J. Liver transplantation in patients over sixty years of age. Transplantation 2001; 72: 679-684.
30. Olthoff KM, Abecassis MM, Emond JC etal. Outcomes for adult living donor liver transplantation: comparison of A2ALL and national experience. Liver Transpl 2011; 17: 789-797.
31. Cross TJS, Antoniades CG, Muiesan P etal. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl 2007; 13: 1382-1388.
32. Yoshizumi T, Shirabe K, Soejima Y etal. Living donor liver transplantation in patients older than 60 years. Transplantation 2010; 90: 433-437.
33. Koga M, Kasayama S. Clinical impact of glycated albumin as another glycemic control marker. Endocr J 2010; 57: 751-762.
34. Shields PL, Tang H, Neuberger J, Gunson BK, McMaster P, Pirenne J. Poor outcome in patient with diabetes mellitus undergoing liver transplantation. Transplantation 1999; 68: 530-535.
35. John PR, Thaluvath PJ. Outcome of liver transplantation in patients with diabetes mellitus: a case-control study. Hepatology 2001; 34: 889-895.
36. Berenguer M. Risk of extended criteria donors in hepatitis C virus-positive recipients. Liver Transpl 2008; 14: S45-S50.
37. Attia M, Silva MA, Mirza DF. The marginal liver donor-an update. Transpl Int 2008; 21: 713-724.